Login to Your Account



Look Out, Folotyn; Istodax Wins Accelerated Approval in PTCL

By Jennifer Boggs


Monday, June 20, 2011
Celgene Corp.'s Istodax (romidepsin) got an accelerated nod, as expected, in peripheral T-cell lymphoma (PTCL) patients who have received at least one prior therapy, pitting it against Allos Therapeutics Inc.'s Folotyn (pralatrexate), a drug that suffered slower-than-expected sales despite being the first approved for PTCL.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription